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ABSTRACT: Assessment of problematic severe asthma in children should be performed in a step-
wise manner to ensure an optimal approach. A four-step assessment scheme is proposed. First, a
full diagnostic work-up is performed to exclude other diseases which mimic asthma. Secondly, a
multi-disciplinary assessment is performed to identify issues that may need attention, including
comorbidities. Thirdly, the pattern of inflammation is assessed, and finally steroid responsiveness
is documented.
Based upon these four steps an optimal individualised treatment plan is developed. In this
article the many gaps in our current knowledge in all these steps are highlighted, and
recommendations for current clinical practice and future research are made.
The lack of good data and the heterogeneity of problematic severe asthma still limit our ability
to optimise the management on an individual basis in this small, but challenging group of
patients.
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A
lthough the majority of children with
asthma respond well to standard therapy,
a significant proportion [1] still have
problematic, severe disease that is not controlled
with conventional management. A birth cohort
identified 4.5% of the asthmatic children with
‘‘severe asthma’’, whereas others found that
39–55% of children with problematic severe asthma
had ‘‘difficult to treat’’ asthma [2, 3]. A recent paper
[4], which discussed definitions, classifications and
age-related presentation of problematic severe
asthma in childhood, suggested asthmatic children
warranted further investigation and outlined trig-
gers of asthma exacerbations. It was emphasised
that many children may have factors apart from the
underlying severity of asthma that contribute to
their severe disease, including comorbidities, socio-
economic problems, adverse environmental expo-
sures (such as tobacco smoke, relevant allergens
and other harmful factors), psychological problems
and especially poor adherence to treatment.
Age is relevant not only for the presentation of
disease and the underlying pathophysiology, but
also for the way the child can be assessed. Our
article focuses on age-appropriate assessment
methods for which there is a scientific basis,
and reports on a step-wise approach to assess
diagnostic possibilities, airway inflammation and
therapeutic responses to corticosteroids (fig. 1).
Essentially, these steps lead to the child being
placed in one of four categories: wrong diagnosis
(‘‘not asthma’’); asthma with significant comor-
bidities that need to be addressed (‘‘asthma
plus’’); asthma which is not responding to
treatment because the basics have not been got
right (‘‘difficult asthma’’); and true asthma
(‘‘severe, therapy-resistant asthma’’). It is patients
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in this last group who would be candidates for the expensive,
and potentially hazardous, cytokine-specific therapies. Treat-
ment of this last group will be covered in another article in this
series. Finally, knowledge gaps will be discussed.
STEP 1: EXCLUDE WRONG DIAGNOSIS
It is crucial to get the diagnosis right. The most important
differential diagnoses and their relevance vary geographically
(e.g. tuberculosis and cystic fibrosis) and particular diagnostic
vigilance should be exercised if the child is non-atopic. Tests
include, but are not limited to: sweat test and genotyping for
cystic fibrosis; nasal nitric oxide and biopsy for primary ciliary
dyskinesia; high-resolution computed tomography (HRCT)
scan for interstitial lung disease, bronchiectasis and airway
malformations; and other relevant tests for systemic disease.
Furthermore, a history of severe, persistent, unusual or
recurrent infections should prompt immunological investigations
including serum immunoglobulin (Ig)G (including subclasses),
IgM and IgA, evaluation of antibody response to common
antigens and vaccines, and HIV testing. Studies of granulocyte
and T-cell function may be warranted. Multisystem conditions,
such as Churg–Strauss syndrome or Wegener’s granulomatosis,
should be considered. A focused approach guided by history
and physical examination is more appropriate than slavishly
performing every possible test on all children.
Clinical recommendation
A detailed re-assessment of the diagnosis should be performed
in all patients whose asthma does not appear to be responding
to treatment. Which test to perform should be based upon local
disease prevalence, but in all patients the minimum tests to
include are: a chest radiograph, Ig and a sweat test.
STEP 2: FULL MULTIDISCIPLINARY ASSESSMENT
In the patient
Lung function
Spirometry and acute bronchodilator reversibility will usually
have been part of Step 1, and failure to demonstrate variable
airflow obstruction over time or with treatment should
definitely lead to the consideration of alternative diagnoses.
Although reduced lung function values are commonly
included in asthma classifications in childhood, the scientific
rationale for this is questionable. The requirement for a
reduction in forced expiratory volume in 1 s (FEV1) as a
diagnostic criterion for severe asthma in children [5, 6] or in
management guidelines [7, 8] will exclude the majority of
children who meet the other diagnostic criteria [9]. Children
with problematic severe asthma have less impairment of lung
function than adults [10–12]. Severe exacerbations appear to be
associated with a more rapid decline in lung function in
children but not adolescents [13]. This may be attenuated by
treatment with inhaled corticosteroids [13]. Since children with
severe asthma may have preserved FEV1, post-bronchodilator
mid-expiratory flow rates, such as forced expiratory flow at
25–75% of forced vital capacity (FEF25–75), FEF50 [10, 14, 15] or
the FEV1/forced vital capacity ratio [12, 14], may be more
sensitive for (better reflecting bronchial obstruction) severe
asthma than FEV1 [12, 14]. However, many children with
genuine severe, therapy-resistant asthma have normal spiro-
metry when asymptomatic.
Nonetheless, spirometry is an important part of the assessment
using relevant reference values [16, 17], since reduced FEV1
strongly supports problematic severe asthma [12]. One drive of
the work-up is to identify children with persistent airflow
limitation. However, for this condition there is no generally
accepted definition in paediatrics and we suggest that children
who, despite an adequate trial of systemic steroids (although
we note that there is no uniformly agreed definition in
paediatrics as to what is an adequate dose or duration) and
acute response to bronchodilator, have an FEV1 of .1.96
Z-scores below the mean should be considered to have
persistent airflow limitation.
Measures of airways resistance are not routinely performed
and their added value to spirometry in assessment of disease
severity is not demonstrated. Furthermore, measures are
technically more challenging than spirometry and interpretation
of measures are less standardised than is the case for spirometry.
Thus, at present, such measures are more useful in research.
Step 1. Exclude wrong diagnosis
Alternative diagnoses, differential 
diagnosis investigations
Minimum chest radiograph
Immunoglobulins
Sweat test
Step 2. Full multidisciplinary 
assessment
Indentify “difficult to treat”
Step 3: Assess pattern of 
inflammation
Step 4: Assess steroid response
Exclude steroid resistance
In the patient:
  Lung function
  Bronchial responsiveness
  Exercise limitation
  Allergy
  Impact of allergen
    avoidance
  Upper airways disease
  Quality of life
  Lung/airway imaging
    including HRCT
  Comorbidities
Environmental:
  Home visit assessment
    (living conditions)
  Environment
  Treatment adherence
  Psychosocial 
    comorbidities
Noninvasive:
  FeNO
  Sputum cell counts
  Exhaled breath and
    breath condensate
  Biobank storage
Invasive:
  Fiberoptic bronchoscopy
  BAL?
Triamcinolone i.m. or
  prednisolone
Complete or partial
  response
FIGURE 1. A step-wise assessment plan is recommended in problematic
severe asthma. HRCT: high-resolution computed tomography; FeNO: exhaled nitric
oxide fraction; BAL: bronchoalveolar lavage.
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Clinical recommendation
Spirometry and measurement of the immediate response to a
bronchodilator should be performed (if age appropriate) in all
children with problematic severe asthma.
Research recommendation
More longitudinal data should be collected on lung function
growth in children with problematic severe asthma.
Assessment of trapped air and other more sophisticated tests
of lung function need scientific evaluation in problematic
severe asthma and may be useful for evaluation of therapy
response and peripheral airflow obstruction.
Bronchial hyperresponsiveness
A bronchial challenge test may already have been performed
as part of Step 1 and if a challenge test is negative in a child
thought to be very symptomatic due to asthma, the diagnosis
should be questioned. The association between increased
bronchial hyperresponsiveness (BHR) and severe asthma
[14, 18, 19] was recently supported by a specificity of 90% of
provocation dose of methacholine causing a 20% fall in
FEV1 (PD20) methacholine of ,0.2 mmol (,1 mmol in [20]) to
discriminate between children with severe versus mild-to-
moderate asthma [12]. The increased BHR in children with
more severe forms of asthma [19] is particularly important in
relation to exercise-induced bronchoconstriction (EIB) [21] and
to a lack of asthma control [22]. The indirect methods,
including standardised exercise test [23], cold air inhalation
with exercise [24], eucapnic voluntary hyperventilation [25] or
inhaled mannitol [26], have different sensitivity and specificity
for the diagnosis of asthma, as well as in response to therapy.
The indirect tests, like exercise and mannitol inhalation are
usually highly specific but with low sensitivity for asthma
[24, 27], although their associations with problematic severe
asthma in childhood is not known. Treatment guided by BHR
measures was found to improve childhood asthma control in
some [28, 29], but not all studies [30]. Although challenge tests
in children with problematic severe asthma are not part of
the routine evaluation in many places, they are important
measures of asthma control [9, 31, 32] and should be
performed in accordance with standardised protocols under
close observation. In some patients, however, such tests cannot
be performed due to bronchial obstruction or other contra-
indications.
Clinical recommendation
Assessing BHR (if baseline conditions allow) and exercise
limitation should be part of routine assessment in problematic
severe asthma whenever possible.
Research recommendation
Establishing the value of EIB testing and other direct and
indirect measures of BHR in differentiating severe from less
severe forms of asthma, as well as their role in monitoring
problematic severe asthma, requires further studies.
Allergy
The risk of severe chronic asthma increases with multiple
sensitisations and high total IgE levels [33, 34]. In fatal
childhood asthma, allergens have been linked to the cause of
death. This particularly relates to food allergens, such as
peanut, but also to airborne allergen exposure such as animal
dander, moulds [35] and high pollen levels in combination with
physical exercise [36]. Hence, a thorough evaluation of possible
allergies and their relevance to clinical disease and severity is
mandatory in a child presenting with problematic severe
asthma. The child’s history is the most important part of that
evaluation but needs to be complemented with further investi-
gations [37]. Allergy testing should be considered in problematic
severe asthma for the following indications: 1) to guide allergen
avoidance measures; 2) if treatment with omalizumab is
considered (this should be preceded by all reasonable attempts
to exclude environmental allergens); 3) to identify the rare child
with severe asthma and fungal sensitisation who may need
avoidance measures and antifungal therapy; 4) if allergic
bronchopulmonary aspergillosis (ABPA) is a possibility; and 5)
to identify the rare non-atopic asthmatic, in whom the possibility
of another diagnosis should be reconsidered.
The standard methods skin-prick testing and response radio-
allergosorbent tests (RAST) may give discordant results and
should probably both be performed. Newly developed
methods enable analysis of multiple antigen components that
may prove helpful in differentiating between allergies that can
cause life-threatening asthma and sensitisations of less
importance for the disease severity [38].
Assessing the impact of allergen avoidance in any child with
problematic severe asthma should be part of the clinical
investigation. The value of house dust mite avoidance for
asthmatic patients has been questioned [3, 39–42], but several
lines of evidence suggest it may be useful in severe asthma.
First, low-dose allergen exposure, insufficient to cause acute
deterioration, may lead to steroid resistance by an interleukin
(IL)-2 and IL-4 dependent mechanism [43, 44]. Secondly, the
combination of viral infection, allergen sensitisation and high
levels of exposure to that allergen in the home are predictive of
severe exacerbations [45], and of these factors only allergen
exposure is amenable to intervention. It is probable that the
expense and inconvenience of allergen avoidance is more likely
to be acceptable in children with severe asthma. In summary,
we believe there is sufficient evidence to recommend avoidance
of aeroallergens where possible in sensitised children with
problematic severe asthma.
With regards to severe asthma with fungal sensitisation, a
randomised controlled trial in adults and case reports in
children suggest a treatment response to itraconazole therapy
[46]. This treatment has the merit of being safe, although the
interaction with budesonide may potentially lead to adrenal
failure and must be considered.
As for ABPA, specific IgE to aspergillus may be a diagnostic
clue which needs to be considered in children with proble-
matic severe asthma and mould sensitisation [35].
Clinical recommendation
Skin prick testing and RAST tests should be part of the routine
clinical work-up in problematic severe asthma, and relevant
allergen avoidance should be instituted for sensitised children.
Research recommendation
Research is needed on: 1) how to respond to discordant results
between RAST and skin prick tests; 2) whether analysis of
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multiple allergen components adds relevant information; 3)
the clinical efficacy of allergen avoidance; and 4) the frequency
and optimal management of severe asthma with fungal
sensitisation.
Upper airways disease
Allergic rhinitis often co-exists with asthma [47] and upper
airway disease may worsen asthma [48]. Treatment of allergic
rhinitis has been advocated as an important component of
asthma management [49, 50], but to what extent treatment of
allergic rhinitis may improve asthma is controversial [51].
Studies on sinusitis treatment in problematic severe childhood
asthma are lacking. However, upper airway evaluation,
including anterior rhinoscopy when appropriate, should be
part of the assessment of problematic severe asthma.
Additional tests including sinus computed tomography (CT)
or magnetic resonance imaging, which are more informative
than plain sinus radiography studies in children, should be
considered [52, 53]. Sinusitis has been reported in a high
proportion of children with severe asthma [54] with or without
nasal symptoms, and a relationship between abnormalities on
sinus CT and bronchial eosinophilic inflammation has been
shown in adults [55, 56]. A trial of treatment for allergic rhinitis
in children with problematic severe asthma would seem
reasonable.
Clinical recommendation
Upper airway assessment is a routine part of the clinical
assessment of problematic severe asthma. Allergic rhinitis
should be treated, although the evidence that this will improve
the asthma is limited.
Research recommendation
We need more work on comparisons of nasal and bronchial
inflammation, and to what extent (if at all) upper airway
samples reflect lower airway inflammatory phenotype.
Quality of life
Functional impairment in daily life is common in asthma [57].
Health-related quality of life (QoL) based on reports from the
child and/or parents provide different information compared
to traditional clinical measurements [58]. Overall, increasing
asthma severity is associated with impaired health-related QoL
[59], although the exact relationship has not always been clear
[60]. We do not have sufficient information to recommend
which QoL questionnaires should be used in problematic
severe asthma, although it would seem sensible to recommend
the use of asthma-specific QoL questionnaires, such as the
Paediatric Asthma Quality of Life Questionnaire (PAQLQ) and
the Paediatric Asthma Caregiver’s Quality of Life Questionnaire
(PACQLQ) [61]. Measures of QoL were recently found to
improve phenotype discrimination in severe asthma [20], but
the value of QoL measures in follow-up studies in severe
asthma needs to be established.
Clinical recommendation
The PAQLQ and the PACQLQ should be available in the
patients’ native language and be completed as part of the
assessment of problematic severe asthma. Optimal frequency
of completing QoL questionnaires for monitoring purposes has
not yet been established.
Research recommendation
More work is required on whether QoL questionnaires
developed for mild and moderate asthma are appropriate for
more severe disease.
Imaging techniques
Specific imaging issues in problematic severe asthma include
the exclusion of other diagnoses (Step 1) and the use of
imaging as a specific, clinically useful biomarker. High-
resolution CT (HRCT) can be used in problematic severe
asthma to study airway wall changes [62, 63]. Bronchial wall
thickening on HRCT has been a consistent finding in children
with problematic severe asthma and it may constitute an
additional criterion of asthma severity [64]. The association
between bronchial wall thickening seen on HRCT scans and
thickness of the bronchial epithelial reticular basement
membrane in bronchial biopsy seen in adult asthmatics has
not been replicated in children [63]. At present there is
insufficient evidence to recommend the routine clinical use
of any imaging technique in problematic severe asthma.
Clinical recommendation
HRCT is not a routine investigation in the assessment of
children with problematic severe asthma, and is only clinically
indicated if there is diagnostic doubt.
Research recommendation
HRCT and other imaging modalities with safe image processing
techniques specifically adapted for the use in children should be
incorporated into research protocols, in order to try to determine
any correlations with airway structure, treatment effects and
prognosis.
Comorbidities: asthma plus
Other comorbidities have been discussed elsewhere [4], and
are an integral part of the assessment. In particular, obesity can
cause a non-inflammatory phenotype, and weight reduction
should be encouraged. There should be a high index of
suspicion for gastro-oesophageal reflux, particularly in young
children.
Environment
Environmental assessments should include a home visit to
ensure the indoor environment is optimal in relation to water
damage, humidity and ventilation, mould exposure, general
irritants, tobacco smoke and allergens.
Among children with difficult to treat asthma, ongoing
environmental allergen exposure may occur in sensitised
children despite advice to the contrary, and thus contribute
to the severity of asthma [33]. Thus, a nurse-led visit to the
child’s home can be an important measure to evaluate the
possible impact of allergy on lack of response to treatment [3].
Other facets of the home visit include assessments of
adherence and psychosocial issues. The nurse should assess
whether there is a complete set of in-date medication readily
available within the home, whether the degree to which the
child is supervised when taking medications is acceptable, and
whether the ability to use the inhaler device is correct. The
nurse should also obtain prescription records, as well as
preferably use objective measures to assess adherence [65].
Merely collecting a prescription does not guarantee that the
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medication has been taken, but not collecting a prescription
means non-adherence is a certainty. Finally, discussions of
sensitive psychosocial issues are more likely to be informative
if they take place in the home.
Clinical recommendation
Where possible, a home visit and detailed assessment of the
environment, adherence, and psychosocial comorbidities
should be performed.
Research recommendation
The longer term value of this intervention needs to be
determined. We also need to know whether repeated visits
and environmental sampling would be beneficial. We need to
have better ways of assessing adherence in routine clinical
practice.
STEP 3: ASSESS PATTERN OF INFLAMMATION
Airway inflammatory markers
Although inflammatory markers in sputum, exhaled air, serum
and urine can be measured, to date they have not been
implemented as part of the clinical management for proble-
matic severe asthma. The justification for their use is that many
children are prescribed ever-higher doses of anti-inflammatory
therapies, which does not seem logical if there is no residual
inflammation. Furthermore, in the future, it is likely that
patterns of inflammation may determine which treatment
should be offered.
Exhaled nitric oxide fraction
Exhaled nitric oxide fraction (FeNO) bears a loose relationship
to eosinophilic airway inflammation. FeNO can predict eosinophil
levels in bronchoalveolar lavage (BAL) [66], and can identify
persistent eosinophilic inflammation in children with steroid-
resistant problematic asthma [67]. Since steroid treatment reduces
FeNO, poor compliance should be suspected if FeNO remains high
despite the prescription of adequate doses of inhaled steroids.
However, it would be a mistake to assume that asthmatic
children who have a high FeNO are non-compliant, there are
other causes, including excessive allergen exposure or steroid
insensitivity. In adults, increased FeNO was recently shown to
predict accelerated decline in lung function in problematic
asthma [68]. It is not clear if the same applies to children. The
measurement of FeNO at different flows may allow partitioning
of NO production to proximal and distal airways.
Inevitably, all children will have been prescribed inhaled
corticosteroids, and the relationship between FeNO and airway
eosinophilia is closest in steroid naı¨ve children. Thus, FeNO in
severe problematic asthma is loosely indicative of the
eosinophilic phenotype. The clinical role of FeNO in proble-
matic severe asthma is still being determined.
Sputum
Sputum is usually obtained after induction with normal or
hypertonic saline [69] after pre-treatment with a bronchodi-
lator [70]. The reported success rate is up to 80% in dedicated
research centres, increasing with patient age and probably
with asthma severity [71–73]. The feasibility of repeated
procedures is problematic in many children, which limits the
clinical usefulness of sputum as a means to detect and monitor
airway inflammation.
Four different inflammatory patterns have been reported:
eosinophilic; neutrophilic; mixed eosinophilic and neutrophilic;
and paucicellular [69]. However, surprisingly, sputum cytology
appeared to be normal in the majority of school-age children
with difficult asthma, with eosinophilia in as few as 30% [71].
The clinical usefulness of soluble sputum markers in childhood
problematic severe asthma has yet to be determined.
Exhaled breath condensate
Condensate from exhaled breath may reflect the composition
of the airway lining fluid [74]. Exhaled breath condensate
(EBC) collection is feasible in children, even during acute
asthma. Few, if any, EBC biomarkers have been validated for
clinical use, and considerable methodological challenges
remain [74]. A recent study [75] demonstrated an increased
level of EBC 8-isoprostane in children with problematic asthma
suggesting a role for oxidative stress in this asthma phenotype.
The use of innovative ‘‘-omics’’ technologies, such as proteomics
and metabolomics, may offer great potential in the future [76].
Other inflammatory markers in serum and urine of (eosino-
philic) inflammation have, in the past, been used for asthma
monitoring and management. These included eosinophilic
products such as eosinophil cationic protein and eosinophil-
derived neurotoxin (eosinophil protein X), as well as cysteinyl-
leukotriene metabolites. Unfortunately, none of these markers
have been shown to be valuable in the diagnosis or monitoring
of asthma, or in severity of the disease in the individual patient,
even if associations have been found in groups of children.
Clinical recommendation
Although assessment of airway inflammation seems intuitively
to be desirable, as yet there is no firm evidence that it is
clinically useful.
Research recommendation
Research protocols should incorporate where feasible: 1) variable
flow FeNO measurements; 2) induced sputum cell counts; 3)
storage of induced sputum supernatant and cell pellets, and EBC
samples in a Biobank; and 4) serum, DNA and urine.
Bronchoscopy
In many paediatric pulmonology centres, fiberoptic broncho-
scopy with BAL, endobronchial biopsy and bronchial brushing
are routinely performed in children with problematic asthma.
In addition to the macroscopic inspection of the large airways
and the diagnosis of any structural defects, this allows for
determination of remodelling and inflammatory responses, in
particular in the proximal airways [10, 77]. More experience is
required to determine the clinical role of these techniques.
Clinical recommendation
Although bronchoscopy is widely used in some centres, as yet
there is no firm evidence that it is useful. It may be indicated if
the diagnosis is in doubt, or to assess structural anomalies,
remodelling and inflammation in difficult cases.
Research recommendation
Research protocols should incorporate bronchoscopy where
feasible, and establish a Biobank for storage of endobronchial
biopsy, BAL fluid and bronchial epithelial cells.
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STEP 4: ASSESS STEROID RESPONSE
Steroid response in childhood is not uniformly defined, and
there is no consensus as to type of test, duration, dosage and
administration form. In terms of how to conduct a steroid trial
for the treatment of difficult asthma in children aged 5–15 yrs,
a recent study evaluated the efficacy of a single dose (in
children aged,10 yrs) or multiple doses (given approximately
once every 4 weeks to children aged .10 yrs) of intramuscular
triamcinolone acetonide [78]. The number and dose of triam-
cinolone was based on clinical judgement, and the total dose
varied from 20 mg to 480 mg. Intramuscular triamcinolone
resulted in significant improvement of a range of severity
markers, and this was sustained beyond the 1 month pharma-
cological activity of the preparation. Thus, intramuscular
triamcinolone might be a useful ‘‘short-term’’ therapy in difficult
asthma in children, and is indicative of the potential steroid effect.
Clinical improvement in symptoms is usually reflected by an
asthma control test. Several tests are available, such as the
Asthma control questionnaire [79] or Asthma Control Test
(ACT) [80]. Inflammatory response may be assessed by
distribution of cell types in sputum or by FeNO if the former
is not available. However, cost-benefit, validity and possible
superiority of one of these methods for assessing steroid
response in children are not clear. The response criteria listed
below are, therefore, provisional and for discussion.
Complete response can be considered: with an improved in
ACT score of 20 or higher; bronchodilator use for symptoms
less than three times a week (excluding during acute viral
infection and its aftermath); normal pre-bronchodilator FEV1
using appropriate reference ranges (no short-acting broncho-
dilator within 4 h of the test); and normal cellularity of induced
sputum/normal FeNO.
Partial response can be considered as failure to meet the
criteria for full response, but a partial response in one or more
criteria is present, defined as: an improvement in the ACT
score of at least 5 points; bronchodilator use reduced by .50%;
FEV1 increase by .12% predicted; in induced sputum a .50%
reduction in eosinophil percentage; and .50% fall in FeNO,
with the same caveats as mentioned previously.
No response can be considered as no significant change in any
of these parameters.
Overall, steroid responsiveness may be considered at two
levels. At the clinical level patients will probably only consider
they have responded to steroids if their symptoms have
improved. Furthermore, some children may respond well to
steroids and yet never regain normal lung function values. At
the research level, to facilitate comparisons between centres,
the assessment of multiple domains of steroid responsiveness
is attractive.
Clinical recommendation
There is no agreed definition of steroid response; probably the
definition most acceptable to patients is improvement of
symptoms.
Research recommendation
The response to a steroid trial should be recorded in terms of
symptoms, spirometry, inflammatory markers and bronchodilator
response, with the ultimate aim of reaching an appropriate
definition of steroid responsiveness.
CURRENT KNOWLEDGE GAPS AND CONCLUSION
It is clear from this article that many techniques are used in the
assessment of children with problematic severe asthma, but
few have been validated. This group of children is very
heterogeneous and no single centre is likely to see enough
patients to be able to conduct randomised trials or move the
field forwards with pathophysiological studies. Thus, interna-
tional collaboration is essential. We suggest that this should
start with a detailed evaluation of these patients using
standardised methods, which will allow for building a large
cohort of carefully characterised patients. The next step is to
move to more objective methods of phenotyping, such as
cluster or principle component analysis, in order to define
homogeneous groups of children. These groups can then be
used: 1) to refine testing and see which of the many techniques
we have described previously is clinically useful; 2) to carry
out randomised controlled trials of specific therapies in
focussed groups of patients; and 3) to carry out mechanistic
studies, including gene association studies, to try to unravel
the question as to what makes this child’s asthma difficult to
control, and why the child does not respond to the simple
medications which are so effective in most children.
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